Skip to main content
Oncopeptides logo

Oncopeptides — Investor Relations & Filings

Ticker · ONCO ISIN · SE0009414576 LEI · 549300J9WWQ5CBYQ1M77 ST Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2021-03-31 Share Issue/Capital Cha…
Country SE Sweden
Listing ST ONCO

About Oncopeptides

https://www.oncopeptides.com/en

Oncopeptides is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company concentrates on hematological diseases, with a primary focus on multiple myeloma. Its commercialized product is Pepaxti (melflufen), a peptide-drug conjugate for adult patients with relapsed or refractory multiple myeloma. Founded in 2000 based on research from leading cancer institutions, Oncopeptides leverages its proprietary technology platforms to advance a pipeline of innovative drug candidates. The company's research also includes the development of Natural Killer (NK) cell engagers to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
Antal aktier och röster i Oncopeptides
Share Issue/Capital Change Classification · 1% confidence The document is a press release dated March 31, 2021, announcing a change in the total number of outstanding shares and votes due to the exercise of stock options under an incentive program. This directly relates to a change in the company's capital structure (increase in shares and share capital). Based on the definitions, this aligns best with the 'Share Issue/Capital Change' category (SHA). It is not an earnings release (ER), a dividend notice (DIV), or a general regulatory filing (RNS), as it concerns a specific capital event.
2021-03-31 Swedish
Major Shareholding Notification 2021
Major Shareholding Notification Classification · 1% confidence The document details a change in the holding of a specific shareholder, HealthCap VI LP, in Oncopeptides AB. It explicitly mentions 'Reason for major shareholding notification' and provides detailed tables showing the 'Before the transaction' and 'After the transaction' quantities of shares and voting rights, along with the resulting percentage. This structure perfectly matches the definition of a Major Shareholding Notification. The filing type code corresponding to this is MRQ.
2021-03-12 English
Major Shareholding Notification 2021
Major Shareholding Notification Classification · 1% confidence The document details a change in shareholding percentage for 'Stiftelsen Industrifonden' in 'Oncopeptides AB'. It explicitly lists 'Reason for major shareholding notification' and provides detailed tables showing the 'Before the transaction' and 'After the transaction' share quantities and resulting percentages. The structure and content directly align with notifications required when an investor crosses a significant ownership threshold. This corresponds to the Major Shareholding Notification category.
2021-03-11 English
Major Shareholding Notification 2021
Major Shareholding Notification Classification · 1% confidence The document details a change in shareholding percentage by a specific holder ('Fjärde AP-fonden') in the issuer ('Oncopeptides AB'). It explicitly shows the 'Before the transaction' and 'After the transaction' quantities of shares and voting rights, crossing a threshold (5%). This type of filing, reporting changes in significant share ownership, directly corresponds to the Major Shareholding Notification category.
2021-03-10 English
Oncopeptides has completed a directed share issue raising approximately SEK 1,106 million (USD 130 million)
Capital/Financing Update Classification · 1% confidence The document is a press release from Oncopeptides AB announcing the completion of a directed share issue (a capital raise). It details the number of shares issued, the subscription price, the gross proceeds, the intended use of funds, and the impact on share capital and dilution. This fits the definition of a 'Capital/Financing Update' (CAP) as it describes a specific financing activity and capital structure change.
2021-03-10 English
Oncopeptides har genomfört en riktad nyemission om cirka 1 106 miljoner kronor (130 miljoner USD)
Capital/Financing Update Classification · 1% confidence The document is a press release dated March 10, 2021, announcing that Oncopeptides AB has successfully completed a directed new share issue (riktad nyemission) raising approximately 1,106 million SEK. The text details the number of shares issued, the subscription price, the use of proceeds (financing commercialization, clinical development, and general operations), dilution effects, and lock-up agreements. This activity directly relates to the company raising capital and changing its capital structure. This aligns perfectly with the definition for 'Capital/Financing Update' (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a simple announcement of a report (RPA/RNS), as it is the primary disclosure of the financing event itself.
2021-03-10 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.